****

**University of Washington / Fred Hutchinson Cancer Research Center**

**Center for AIDS Research (CFAR)**

**2015 Request for Applications (RFA)**

**International Pilot Awards**

|  |  |
| --- | --- |
| **Key Deadlines** | **Date Due** |
| RFA Release Date | September 1, 2015 |
| Behavioral or Biomedical Intervention Eligibility Check | October 2, 2015 |
| Applications Due | October 19, 2015 |

See the following pages for a description of the award program and application process.

**International Pilot Awards**

Purpose

The international pilot awards are for development and implementation of innovative and collaborative HIV-related research projects in developing countries by junior faculty. Pilot awards provide an opportunity to initiate new research or to leverage new directions for research within ongoing projects that will provide important preliminary data to seed future larger proposals by junior investigators in international settings. Studies with potential to obtain pilot data for development of future grant proposals are given priority.

Eligibility

To be eligible, a PI must be a junior investigator at a UW/FHCRC CFAR affiliated institution: Fred Hutchinson Cancer Research Center, Seattle BioMed, Seattle Children’s, University of Hawaii and affiliated international institutions (listed [here](https://depts.washington.edu/cfar/sites/default/files/uploads/Eligible%20Institutions.docx)).

1. Junior investigators are defined as:

* Current UW junior faculty (including acting positions through Assistant Professor) who have not had an R01 grant in HIV/AIDS. Senior applicants may apply if the proposal reflects a new research direction.
* Scientists completing fellowships
* Senior post-doctoral fellows
* Junior faculty being recruited to the UW faculty or affiliated institutions
* Investigators with comparable appointments at UW-affiliated institutions

1. Each international PI must partner with a faculty co-investigator from the University of Washington or UW-affiliated institutions.
2. If the PI is a US-based applicant, an international co-investigator must be included in key personnel.

Contact [cfarintl@uw.edu](mailto:cfarintl@uw.edu) if you have questions about eligibility.

Types of projects

Research topics could include any aspect of HIV and HIV-related research, but may not include prospective human interventional trials (e.g. clinical trials of new drugs, treatments, or devices; or off-label use of a licensed drug). Studies of animal models, stored samples from existing cohorts, small pathogenesis studies or *in vitro*trials are acceptable. Project must be primarily conducted in an international location.

If your proposed study design involves testing a biomedical or behavioral intervention (including approved drugs and/or standard of care), please contact the International Core Program Manager by Friday, October 2, 2015 to determine whether the proposed project would be eligible for funding at [cfarintl@uw.edu](mailto:cfarintl@uw.edu). Please include a brief description of 1) the study group(s), 2) the planned intervention and how it will be assigned, and 3) your proposed outcomes.

Funding Available

Direct costs: $15,000 US over one year. Previously funded projects will not be considered. Funding cannot be applied to alterations or renovations of any facilities or IRB/ERC fees. If the proposal requires a sub-contract, subcontractor F&A costs must be budgeted as a direct cost. Please note that the CFAR has negotiated indirect cost waivers with several local institutions, including Fred Hutch, CIDR (formerly Seattle BioMed) and Seattle Children’s. For international institutions, the allowable F&A rate to be budgeted as a direct cost is 8%. For domestic organizations without an established F&A rate, the default F&A rate is 10%.  If the proposal funds work through UW Kenya, the 13% UW Kenya recharge fee must be budgeted as a direct cost.

Pre-Submission Requirements

Intervention Eligibility Check: If your proposed study design involves testing a biomedical or behavioral intervention (including approved drugs and/or standard of care), please contact the International Core Program Manager by Friday, October 2, 2015 to determine whether the proposed project would be eligible for funding at [cfarintl@uw.edu](mailto:cfarintl@uw.edu). Please include a brief description of 1) the study group(s), 2) the planned intervention and how it will be assigned, and 3) your proposed outcomes.

Letters of Support: Applications must include letters of support from all key personnel including faculty co-investigator(s).

CFAR Membership: All applicants are required to be UW/FHCRC CFAR Members. Information about membership can be found at <http://depts.washington.edu/cfar/get-involved/cfar-membership> or by contacting Michelle Ward ([middlemj@uw.edu](mailto:middlemj@uw.edu)).

Pre-Submission Recommendation:

Biostatistical Consultation: All applicants strongly advised to discuss their proposal with one of CFAR’s biostatisticians prior to/during the preparation of their application, as the proposals will be evaluated for statistical content. If you are a local investigator, please contact Sarah Holte (sholte@fhcrc.org) to schedule your in-person biostatistical review. You will be required to submit a draft of your methods 48 hours before your consultation. If you are an international investigator, please send a copy of your draft methods to Julia Dettinger (jcdettin@uw.edu) and she will arrange your written consultation with a CFAR biostatistician.

Review Criteria

**Significance**: Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced?

**Approach**: Are the conceptual framework, design, methods, and analyses adequate and appropriate to the aims of the project?

**Innovation**: Does the project employ novel concepts, approaches or method? Are the aims original and innovative?

**Investigators** (including relationship to UW/FHCRC CFAR): Is the investigator appropriately trained and well suited to carry out this work? CFAR prioritizes junior investigators and the investigators must meet the eligibility criteria described above.

**Environment**: Does the scientific environment in which the work will be done contribute to the probability of success? Is there evidence of institutional support? Though projects in any country are eligible, CFAR International target countries include Peru, Kenya, Mozambique, Senegal, Uganda and China.

**Feasibility**: Is the study feasible given the duration of one year and a budget of $15,000?

**Potential for new collaborations**: Although we prioritize CFAR links and target particular countries, we are also encouraging relationships with new investigators who are not currently linked to CFAR. We welcome new investigators who bring expertise in new, relevant disciplines to forge interdisciplinary collaborations.

**Potential for new research projects and career development**: The projects should aid in the development of the investigator by providing important data for a larger NIH (or other) funded study such as an R01.

Pre-Award Requirements

Per NIH policy, UW/FHCRC CFAR may not release pilot research funds until awardees complete the NIH administrative clearance process. Clearance will require final IRB approval from all participating institutions and documentation of human subjects training from all investigators. This process often takes several months, so please consider it in your timeline. More information on NIH requirements for international studies can be found at:

<http://www.niaid.nih.gov/LabsAndResources/resources/cfar/Pages/reportingRequirements.aspx>

\*\*Projects that are unable to complete the NIH clearance process within one year of award date are at risk of losing funding\*\*

Post-Award Requirements

CFAR support must be acknowledged in all publications derived from CFAR funding. Suggested wording is available [here](http://depts.washington.edu/cfar/discover-cfar/acknowledge-cfar).

A progress report is required annually and upon completion of the project. This should include information about publications, collaborations, and future grants related to your CFAR project.

Application Instructions

After fulfilling all pre-submission requirements, submit your application by **October 19, 2015** to [cfarintl@uw.edu](mailto:cfarintl@uw.edu) using the following application form. The application, any letters of support, biosketches and any other supporting documentation must be combined into a single PDF. Application sections can be expanded or shortened, however proposal narratives (the application form sections 1 – 12, excluding the budget and biosketches) should be no longer than **five** pages.

Use of CFAR Resources:

We encourage all applicants to use or contact CFAR Cores or link to CFAR Scientific Working Groups (see below). Information about other CFAR cores and services can be found at <http://depts.washington.edu/cfar/find-a-service>.

Sociobehavioral Study Consultation: Applicants have the opportunity to have an expert from the Sociobehavioral and Prevention Research Core consult with them regarding their study design. In order to receive this consultation, applicants should contact cfarintl@uw.edu.

Immunological Study Consultation: Applicants proposing an immunology or other appropriate basic research study have the opportunity to have an expert from the Immunology Core consult with them regarding their experimental design. In order to receive this consultation, applicants should contact cfarintl@uw.edu.

Implementation Science Study Consultation: Applicants proposing a study in the field of implementation science have the opportunity to have an expert from the Implementation Science Working Group consult with them regarding their study. In order to receive this consultation, applicants should contact cfarintl@uw.edu.

Health Economics Impact Study Team (HEIST): Applicants proposing to incorporate health economics methods into their study have the opportunity to have an expert in health economics consult with them regarding experimental design. In order to receive this consultation, applicants should contact cfarintl@uw.edu.

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **UW/FHCRC Center for AIDS Research**  **C:\Users\geneh.NEBULA2\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.Outlook\BCMI2GZZ\CFAR-logo outlined.jpg2015 Pilot Award Application** | | | | | | | | | | | |
|  | | | | | | | | | | | |
|  |  |  |  |  |  | | |  | |  |  |
| **1. Title of Project** | | | | | | | | | | | |
| City and Country of Project: | | | | | Field Site: | | | | | | |
|  |  |  |  |  |  | | |  | |  |  |
| **2. Principal Investigator** | | | |  |  | | |  | |  |  |
| Name and Title: | | | | | | | | | | | |
| Organization: | | | | | | | | | | | |
| Address: | | | | | | | | | | | |
| City: | | | State: | | | Zip: | | | | | |
| Phone: | | | Fax: | | | | Email: | |  | | |
|  |  |  |  |  |  | | |  | |  |  |
| **3. Collaborating Investigator** | | | | | | | | | |  |  |
| Name and Title: | | | | | | | | | | | |
| Organization: | | | | | | | | | | | |
| Address: | | | | | | | | | | | |
| City: | | | Country: | | | | | | | | |
| Phone: | | | Fax: | | | | Email: | |  | | |
|  |  |  |  |  |  | | |  | |  |  |
| **4. Background Statement** | | |  |  |  | | |  | |  |  |
|  | | | | | | | | | | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **5. Study Description (Include objectives, study population, and methodology)** | | | | | | | |  |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
| **6. Site (City, Country and Treatment Setting)** | | | | |  |  |  |  |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  |  |  |  |  |  |  |  |  |
| **7. FWA # for all sites** | |  |  |  |  |  |  |  |
| Institution |  |  |  |  | Number |  |  |  |
|  | | | | |  | | | |
|  | | | | |  | | | |
|  | | | | |  | | | |
|  |  |  |  |  |  |  |  |  |
| **8. Describe in lay language how human subjects protection will be maintained (confidentiality, risk and benefits of participation, minimizing risk of harm, and informed consent)** | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  |  |  |  |  |  |  |  |  |
| **9. Describe your future plans for the data you will collect in this study and how this pilot study will promote career development and/or new collaborative research activities.** | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  | | | | | | | | |
|  |  |  |  |  |  |  |  |  |
| **10. IRB # if approved or applying for a modification.** | | | | | | |  |  |
| **(if no number, state plan for human subjects approval: new, pending modification, etc.)** | | | | | | | | |
| Study | | | | Number | | PI | | |
|  | | | |  | |  | | |
|  | | | |  | |  | | |
|  |  |  |  |  |  |  |  |  |
| **11. Describe any NIH programs linked to this study** | | | | | |  |  |  |
| Title | | | | Grant # | | PI | | |
|  | | | |  | |  | | |
|  | | | |  | |  | | |
|  | | | |  | |  | | |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **12. Co-Investigators** | |  |  |  |  |  |  |  |
| Name | | | Affiliation |  |  | Email |  |  |
|  | | |  | | |  | | |
|  | | |  | | |  | | |
|  | | |  | | |  | | |
|  | | |  | | |  | | |
|  | | |  | | |  | | |
|  |  |  |  |  |  |  |  |  |
| **Attach: Biosketches of key personnel**  **Letters of support from key personnel and UW mentor** | | | | | | | | |
|  |  |  |  |  |  |  |  |  |
| Please note: If your application is selected, all investigators will need to complete Human Subjects Training. Link to free on-line training is available at: http://depts.washington.edu/cfar/citi\_info | | | | | | | | |
|  |  |  |  |  |  |  |  |  |
| **Submit application to cfarintl@uw.edu by October 19, 2015.** | | | | | | | | |

|  |  |  |
| --- | --- | --- |
| DETAILED BUDGET FOR INITIAL BUDGET PERIODDIRECT COSTS ONLY | FROM | THROUGH |
|  |  |

List PERSONNEL *(Applicant organization only),* Use Cal, Acad, or Summer to Enter Months Devoted to Project

Enter Dollar Amounts Requested *(omit cents)* for Salary Requested and Fringe Benefits

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| NAME | ROLE ON PROJECT | Cal.  Mnths | Acad.  Mnths | Summer  Mnths | | INST.BASE SALARY | SALARY REQUESTED | FRINGE BENEFITS | | TOTAL |
|  | PD/PI |  |  |  | |  |  |  | |  |
|  |  |  |  |  | |  |  |  | |  |
|  |  |  |  |  | |  |  |  | |  |
|  |  |  |  |  | |  |  |  | |  |
|  |  |  |  |  | |  |  |  | |  |
|  |  |  |  |  | |  |  |  | |  |
|  |  |  |  |  | |  |  |  | |  |
| SUBTOTALS | | | | | | |  |  | |  |
| CONSULTANT COSTS | | | | | | | | | |  |
| EQUIPMENT *(Itemize)* | | | | | | | | | |  |
| SUPPLIES *(Itemize by category)* | | | | | | | | | |  |
| TRAVEL | | | | | | | | | |  |
| INPATIENT CARE COSTS | | | | | | | | | |  |
| OUTPATIENT CARE COSTS | | | | | | | | | |  |
| ALTERATIONS AND RENOVATIONS *(Itemize by category)* | | | | | | | | | |  |
| OTHER EXPENSES *(Itemize by category)* | | | | | | | | | |  |
| CONSORTIUM/CONTRACTUAL COSTS | | | | | DIRECT COSTS | | | |  | |
| SUBTOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD *(Item 7a, Face Page)* | | | | | | | | | $ |  |
| CONSORTIUM/CONTRACTUAL COSTS | | | | | FACILITIES AND ADMINISTRATIVE COSTS | | | |  | |
| TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD | | | | | | | | | $ |  |

**BUDGET JUSTIFICATION PAGE**